Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics
MDxHealth SA announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco (Epi)genomics.
The mission of the Center is to accelerate innovation in personalized medicine by using advanced technology, knowledge and expertise in (epi)genetics. The Center will bring together scientific expertise from disease centered basic researchers, corresponding clinical validation teams, bioinformaticians, and cutting edge (epi)genomic technology focused on the discovery of effective individualized epigenetic-based diagnostic and personalized therapeutic products.
As a result of several years of productive collaboration between the Laboratory of Bioinformatics and Computational Genomics (BIOBIX), NXTGNT (UGent genome analysis facility), the Biomarked valorization consortium teams and MDxHealth, the new Center is located at Ghent University within the laboratory of Pharmaceutical Biotechnology. The facility will house MDxHealth's research team and lab equipment for development of epigenetic tests together with the Ghent University team for (epi)genetic sequencing. The facility works in close collaboration with the Laboratory of Bioinformatics and Computational Genomics, located at the Faculty of BioEngeneering, providing extensive expertise in epigenetic characterization and computing and visualization of (epi)genomic datasets. The Center is fully operational as off December 1, 2012.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

RocketVax AG - Basel, Switzerland

Oral peptides: A new era in drug development - The research opens the door to a new class of orally available drugs, addressing a long-standing challenge in the pharmaceutical industry
DeCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics - Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer
Affimed Therapeutics AG expands clinical development team
Beer. Soup. Barley's next great use? A medical imaging drink

Forest Discovery: Trees Trade Carbon Among Each Other
Eppendorf with new CEO dual leadership - Former CEO, Thomas Bachmann, left the company

Dunn Labortechnik celebrates its 30th anniversary
Growing Fuel and Medicine: Advancing Biofuels and Plant-Produced Therapeutics - Scientists from WPI and the Arkansas Bioscience Institute Present their Latest Research on Cellulosic

Cell-free quest for new antibiotics - A new method combines synthetic biology with artificial intelligence
STA Pharmaceutical to open new transition metal catalysis center
